Bruce E. Brockstein, MD | NorthShore

Dr. Bruce E. Brockstein

Claim this profile

NorthShore University HealthSystem-Evanston Hospital

Studies Brain Tumor
Studies Glioblastoma
11 reported clinical trials
21 drugs studied

Area of expertise

1Brain Tumor
Bruce E. Brockstein has run 2 trials for Brain Tumor. Some of their research focus areas include:
Stage IV
2Glioblastoma
Bruce E. Brockstein has run 2 trials for Glioblastoma. Some of their research focus areas include:
TMB
EGFR
+7/-10

Affiliated Hospitals

Image of trial facility.
NorthShore University HealthSystem-Evanston Hospital
Image of trial facility.
NorthShore University HealthSystem-Glenbrook Hospital

Clinical Trials Bruce E. Brockstein is currently running

Image of trial facility.

Nivolumab + Ipilimumab + Sargramostim

for Advanced Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria

More about Bruce E. Brockstein

Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Bruce E. Brockstein has experience with
  • Nivolumab
  • Ipilimumab
  • Radiation Therapy
  • Cisplatin
  • Intensity-Modulated Radiation Therapy
  • Single Fraction Stereotactic Radiosurgery

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Bruce E. Brockstein specialize in?
Is Bruce E. Brockstein currently recruiting for clinical trials?
Are there any treatments that Bruce E. Brockstein has studied deeply?
What is the best way to schedule an appointment with Bruce E. Brockstein?
What is the office address of Bruce E. Brockstein?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security